Company Advaxis, Inc. Nasdaq

Ayala Pharmaceuticals, Inc., formerly Advaxis, Inc., is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It is also developing Lm-based antigen delivery products for patients suffering from more common cancers. The Company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors, including desmoid tumors, and ADXS-504, a Lm-based therapy for early-stage prostate cancer. It uses a combination of sequencing and its bioinformatics platform to help develop Notch-targeted therapies. It is evaluating AL102 in its Phase II/III RINGSIDE trial for the treatment of patients with progressing desmoid tumors. It is also evaluating AL101 in a Phase II trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).